Co-founder and CEO
Cyta Therapeutics, Inc.
Ms. Fendrock is a life science entrepreneur and executive. Ms. Fendrock is the CEO and Cofounder of Cyta Therapeutics, a spin-out from UMass, Amherst. Cyta is developing targeted therapeutics based on the polymeric nanogel chemistry of Professor S. “Thai” Thayumanavan. Prior to Cyta, Ms. Fendrock was CEO and Co-founder of Hepregen Corporation, a venture backed, commercial stage, MIT spin-out based on Professor Sangeeta Bhatia’s bioengineered technology. With over 25 years of experience in life sciences, Ms. Fendrock has worked in high growth, environments where efficient execution to build new businesses is at a premium. Ms. Fendrock held management roles in foundational biotechnology companies including Genzyme, Somatix (one of the first gene therapy companies), Genetics Institute and Acusphere. She worked in research and product development at Integrated Genetics and Centocor. In 2012, Ms. Fendrock was honored along with other innovation leaders as one of the Mass High Tech ‘Women to Watch’. Ms Fendrock is a Director, Executive Women Series, for the Boston Chapter of the Healthcare Businesswomen’s Association (HBA) and volunteers as a mentor to entrepreneurs. Education: B.A., Molecular Biology, Wellesley College S.M., Interdisciplinary Science, MIT M.B.A., The Wharton School, University of Pennsylvania; Management of Technology Fellow